Hypertension is a major cardiovascular and
cerebrovascular risk factor and is highly prevalent throughout
the world, affecting 50% of people over 60 years of age. Angiotensin-converting enzyme (ACE) inhibitors are the gold
standard in the treatment of hypertension. However, there exist important differences among the available ACE inhibitors.
Perindopril is distinguished based on specific characteristics,
such as long duration of action, 24-hour blood pressure control, high lipophilicity, and high tissue ACE affinity. Moreover,
clinical studies investigating the effects of perindopril on morbidity and mortality have provided evidence of its benefits
along cardiovascular disease continuum. Since inappropriate
treatment was one of the most important reasons for the inadequate blood pressure control, the high efficacy and safety
of Perineva® (Krka’s perindopril) and its availability in a variety of dosage forms, strengths and fixed-dose combinations
might facilitate the management of hypertension and improve
compliance among the Croatian patient
